{"id":"vegf-trap-eye-bay86-5321","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hemorrhage"},{"rate":null,"effect":"Eye pain"},{"rate":null,"effect":"Floaters"},{"rate":null,"effect":"Intraocular inflammation"},{"rate":null,"effect":"Endophthalmitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"VEGF Trap-Eye functions as a fusion protein combining VEGF-binding domains from VEGF receptors with the Fc portion of human immunoglobulin. It acts as a molecular 'trap' that sequesters circulating VEGF and VEGF-B, preventing their interaction with endogenous VEGF receptors on endothelial cells. This blocks the pathological neovascularization and vascular permeability that characterize wet age-related macular degeneration and other retinal diseases.","oneSentence":"VEGF Trap-Eye is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel growth in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:54.428Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Wet age-related macular degeneration (AMD)"},{"name":"Diabetic macular edema (DME)"},{"name":"Retinal vein occlusion (RVO)"}]},"trialDetails":[{"nctId":"NCT06075147","phase":"","title":"The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2024-02-15","conditions":"Visual Impairment, Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macula Edema (DME)","enrollment":2500},{"nctId":"NCT05705258","phase":"","title":"A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)","status":"RECRUITING","sponsor":"Bayer","startDate":"2023-03-27","conditions":"Retinopathy of Prematurity, Newborns, Infants","enrollment":75},{"nctId":"NCT05850520","phase":"PHASE3","title":"A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-05-15","conditions":"Macular Edema Secondary to Retinal Vein Occlusion","enrollment":892},{"nctId":"NCT05511038","phase":"PHASE4","title":"A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-08-26","conditions":"Diabetic Macular Edema","enrollment":100},{"nctId":"NCT04423718","phase":"PHASE3","title":"Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-08-11","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":1011},{"nctId":"NCT04429503","phase":"PHASE2, PHASE3","title":"Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-06-29","conditions":"Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus","enrollment":660},{"nctId":"NCT06662994","phase":"PHASE4","title":"High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy","status":"RECRUITING","sponsor":"Retina Consultants of Orange County","startDate":"2025-07-07","conditions":"Diabetic Macular Edema (DME)","enrollment":15},{"nctId":"NCT05989126","phase":"PHASE3","title":"Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-04-15","conditions":"Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":35},{"nctId":"NCT05473715","phase":"PHASE4","title":"A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment","status":"TERMINATED","sponsor":"Bayer","startDate":"2023-04-25","conditions":"Neovascular (Wet) Age-related Macular Degeneration","enrollment":3},{"nctId":"NCT03939767","phase":"","title":"Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-05-12","conditions":"Wet Age-related Macular Degeneration","enrollment":1563},{"nctId":"NCT01331681","phase":"PHASE3","title":"Intravitreal Aflibercept Injection in Vision Impairment Due to DME","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-05-09","conditions":"Diabetes Mellitus, Macular Edema","enrollment":406},{"nctId":"NCT02305238","phase":"PHASE4","title":"Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-12-19","conditions":"Wet Macular Degeneration","enrollment":288},{"nctId":"NCT02581891","phase":"PHASE4","title":"Managing Neovascular (Known as \"Wet\") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-11-19","conditions":"Macular Degeneration","enrollment":287},{"nctId":"NCT02289924","phase":"","title":"Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-01-09","conditions":"Wet Macular Degeneration","enrollment":912},{"nctId":"NCT02924311","phase":"","title":"Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-09-21","conditions":"Diabetic Retinopathy","enrollment":402},{"nctId":"NCT01783925","phase":"","title":"Eylea Post Marketing Surveillance(PMS)","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-04-29","conditions":"Macular Degeneration","enrollment":3206},{"nctId":"NCT02279537","phase":"","title":"Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-01-02","conditions":"Wet Macular Degeneration","enrollment":593},{"nctId":"NCT03714308","phase":"","title":"Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-01-28","conditions":"Macular Degeneration","enrollment":554},{"nctId":"NCT04101721","phase":"PHASE3","title":"Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2019-10-30","conditions":"Retinopathy of Prematurity","enrollment":127},{"nctId":"NCT04524910","phase":"","title":"A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV)","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-06-16","conditions":"Myopic Choroidal Neovascularization","enrollment":28},{"nctId":"NCT01756248","phase":"","title":"EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-12-26","conditions":"Macular Degeneration","enrollment":3872},{"nctId":"NCT04137120","phase":"","title":"Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-02-19","conditions":"Retinal Disease","enrollment":73},{"nctId":"NCT02157077","phase":"PHASE3","title":"Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2013-12","conditions":"Macular Degeneration, Wet Macular Degeneration, Retinal Degeneration","enrollment":90},{"nctId":"NCT04641234","phase":"","title":"A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD).","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-12-11","conditions":"Neovascular Age-related Macular Degeneration","enrollment":330},{"nctId":"NCT04004208","phase":"PHASE3","title":"Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-09-25","conditions":"Retinopathy of Prematurity (ROP)","enrollment":113},{"nctId":"NCT02850263","phase":"","title":"A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-07-05","conditions":"Macular Edema","enrollment":750},{"nctId":"NCT03470103","phase":"","title":"A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-03-28","conditions":"Macular Degeneration","enrollment":643},{"nctId":"NCT02540954","phase":"PHASE3","title":"Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-09-29","conditions":"Macular Degeneration","enrollment":336},{"nctId":"NCT02120950","phase":"PHASE4","title":"Aflibercept in Polypoidal Choroidal Vasculopathy","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-05-29","conditions":"Neovascular Macular Degeneration","enrollment":333},{"nctId":"NCT02821247","phase":"","title":"Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-07-01","conditions":"Choroidal Neovascularization, Macular Degeneration","enrollment":119},{"nctId":"NCT02818998","phase":"PHASE3","title":"Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-11-16","conditions":"Macular Edema","enrollment":463},{"nctId":"NCT03639675","phase":"PHASE3","title":"Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-10-03","conditions":"Glaucoma, Neovascular","enrollment":16},{"nctId":"NCT03521895","phase":"","title":"An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-05-01","conditions":"Macular Degeneration","enrollment":1000},{"nctId":"NCT03411941","phase":"","title":"Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-02-28","conditions":"Macular Degeneration","enrollment":116},{"nctId":"NCT02260687","phase":"","title":"Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-12-05","conditions":"Choroidal Neovascularization","enrollment":353},{"nctId":"NCT02811692","phase":"","title":"Study for Collection of Aflibercept Data in Routine Practice","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-09-30","conditions":"Eye Diseases","enrollment":425},{"nctId":"NCT02040220","phase":"","title":"Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO)","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-01-24","conditions":"Retinal Vein Occlusion","enrollment":385},{"nctId":"NCT02540369","phase":"","title":"To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-12-14","conditions":"Wet Macular Degeneration","enrollment":2150},{"nctId":"NCT02581995","phase":"PHASE4","title":"Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-11-19","conditions":"Macular Edema","enrollment":560},{"nctId":"NCT01756261","phase":"","title":"EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-12-26","conditions":"Macular Degeneration","enrollment":757},{"nctId":"NCT01914380","phase":"","title":"Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-07-29","conditions":"Wet Age-related Macular Degeneration","enrollment":988},{"nctId":"NCT02615496","phase":"","title":"Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-12-07","conditions":"Macular Degeneration","enrollment":716},{"nctId":"NCT02541084","phase":"","title":"Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-08-18","conditions":"Wet Macular Degeneration","enrollment":72},{"nctId":"NCT02585401","phase":"","title":"Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-18","conditions":"Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO), Diabetic Macular Edema (DME)","enrollment":99},{"nctId":"NCT01482910","phase":"PHASE3","title":"VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12","conditions":"Macular Degeneration","enrollment":304},{"nctId":"NCT01363440","phase":"PHASE3","title":"Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2011-05","conditions":"Diabetic Macular Edema","enrollment":466},{"nctId":"NCT01783886","phase":"PHASE3","title":"Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-02","conditions":"Macular Edema","enrollment":381},{"nctId":"NCT00964795","phase":"PHASE3","title":"Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular (\"Wet\") Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2009-12","conditions":"Neovascular Age-related Macular Degeneration","enrollment":323},{"nctId":"NCT00637377","phase":"PHASE3","title":"Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-04","conditions":"Macular Degeneration","enrollment":1240},{"nctId":"NCT01521559","phase":"PHASE3","title":"Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-04","conditions":"Branch Retinal Vein Occlusion","enrollment":183},{"nctId":"NCT01012973","phase":"PHASE3","title":"Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-10","conditions":"Retinal Vein Occlusion","enrollment":177},{"nctId":"NCT01512966","phase":"PHASE3","title":"Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-01","conditions":"Macular Edema","enrollment":73},{"nctId":"NCT00789477","phase":"PHASE2","title":"DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2008-12","conditions":"Diabetic Macular Edema","enrollment":221},{"nctId":"NCT01249664","phase":"PHASE3","title":"VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-12","conditions":"Myopia, Pathological","enrollment":122},{"nctId":"NCT00509795","phase":"PHASE3","title":"Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2007-08","conditions":"Macular Degeneration","enrollment":1217},{"nctId":"NCT00320788","phase":"PHASE2","title":"Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2006-04","conditions":"Macular Degeneration","enrollment":159}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VEGF Trap-Eye (BAY86-5321)","genericName":"VEGF Trap-Eye (BAY86-5321)","companyName":"Bayer","companyId":"bayer","modality":"Biologic","firstApprovalDate":"","aiSummary":"VEGF Trap-Eye is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel growth in the eye. Used for Wet age-related macular degeneration (AMD), Diabetic macular edema (DME), Retinal vein occlusion (RVO).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}